Dallas, Texas (PRWEB) July 07, 2013 <\/p>\n
The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the world's leading healthcare companies: <\/p>\n
Trends in gene therapy partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Gene therapy partnering contract documents Top gene therapy deals by value <\/p>\n
The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals (http:\/\/www.reportsnreports.com\/reports\/262461-gene-therapy-partnering-terms-and-agreements.html<\/a>). The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. <\/p>\n This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors. <\/p>\n Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not. <\/p>\n This report contains a comprehensive listing of all gene therapy partnering deals announced since 2007 including financial terms where available including over 300 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. <\/p>\n Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal. <\/p>\n For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? <\/p>\n The report also includes numerous tables and figures that illustrate the trends and activities in gene therapy partnering and dealmaking since 2007. <\/p>\n <\/p>\n Follow this link:<\/p>\n Gene Therapy Partnering Deals & Agreements By Healthcare Companies Analyzed in New Research Report at ReportsnReports ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Dallas, Texas (PRWEB) July 07, 2013 The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the world's leading healthcare companies: Trends in gene therapy partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Gene therapy partnering contract documents Top gene therapy deals by value The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals (http:\/\/www.reportsnreports.com\/reports\/262461-gene-therapy-partnering-terms-and-agreements.html<\/a>). Continue reading